Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: Analysis of therapeutic drug monitoring data under naturalistic conditions

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 206-211

  Unterecker, Stefan ^a   Reif, Andreas ^a   Hempel, Susanne ^a   Proft, Florian ^a   Riederer, Peter ^a   Deckert, Jürgen ^a   Pfuhlmann, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

antidepressants; doxepin; interaction; valproic acid; venlafaxine

Indexed keywords

DOXEPIN; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CYCLOHEXANOL DERIVATIVE; GABAERGIC RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; BIOTRANSFORMATION; BLOOD; COMPARATIVE STUDY; DEPRESSION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GERMANY; MIDDLE AGED; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; CYCLOHEXANOLS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXEPIN; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GABA AGENTS; GERMANY; HISTAMINE ANTAGONISTS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; VALPROIC ACID;

EID: 84902153129     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000025     Document Type: Article

References (32)

1. Amsterdam JD, Brunswick DJ (2003). Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 5:388-395. (Pubitemid 38072241)
2. Angalakuditi M, Angalakuditi N (2011). A comprehensive review of the literature on epilepsy in selected countries in emerging markets. Neuropsychiatr Dis Treat 7:585-597.
3. Avoni P, Riva R, Albani F (1996). Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol 3:272-274. (Pubitemid 26184312)
4. Bisdorff AR (2011). Management of vestibular migraine. Ther Adv Neurol Disord 4:183-191.
5. Bond DJ, Lam RW, Yatham LN (2010). Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and metaanalysis. J Affect Disord 124:228-234.
6. Bowden CL (2003). Valproate. Bipolar Disord 5:189-202.
7. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, et al. (2011). Evidence-based guideline: treatment of painful diabetic neuropathy - report of the American association of neuromuscular and electrodiagnostic medicine, the American academy of neurology, and the American academy of physical medicine &rehabilitation. Muscle Nerve 43:910-917.
8. DeToledo JC, Haddad H, Ramsay RE (1997). Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 19: 71-73. (Pubitemid 28068998)
9. Dietrich DE, Emrich HM (1998). The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 59:51-58.
10. Fehr C, Gründer G, Hiemke C, Dahmen N (2000). Increase of serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 20:493-494. (Pubitemid 30463771)
11. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, et al. (1999). O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480-490. (Pubitemid 29123875)
12. Fu C, Katzman M, Goldbloom DS (1994). Valproate/nortriptyline interaction. J Clin Psychopharmacol 14:205-206.
13. Haritos VS, Ghabrial H, Ahokas JT, Ching MS (2000). Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 10:591-603.
14. Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C (2002). The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 19:1034-1037. (Pubitemid 34804247)
15. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. (2011). AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44:195-235.
16. Joseph AB, Wroblewski BA (1993). Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. Brain Inj 7:463-465. (Pubitemid 23262793)
17. Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J (2002). Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 12:571-580. (Pubitemid 35177088)
18. Koszewska I, Rybakowski JK (2009). Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 59:12-16.
19. McAlpine DE, Biernacka JM, Mrazek DA, OKane DJ, Stevens SR, Langman LJ, et al. (2011). Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 33:14-20.
20. Miller JM, Kustra RP, Vuong A, Hammer AE, Messenheimer JA (2008). Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 68:1493-1509. (Pubitemid 352001187)
21. Patsalos PN, Perucca E (2003). Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2:473-481. (Pubitemid 36876104)
22. Perucca E (2005). Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246-255.
23. Pisani F, Primerano G, Amendola DAgostino A, Spina E, Fazio A (1986). Valproic acid-amitriptyline interaction in man. Ther Drug Monit 8:382-383. (Pubitemid 16040557)
24. Roberts-Thomson KC, Teo KS, Young GD (2007). Drug-induced Brugada syndrome with ST-T wave alternans and long QT. Intern Med J 37: 199-200.
25. Shams MEE, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, et al. (2006). CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493-502. (Pubitemid 44337299)
26. Spina E, Perucca E (2002). Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43:37-44. (Pubitemid 34229485)
27. Stephen LJ (2003). Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 20:141-152. (Pubitemid 36246296)
28. Unterecker S, Burger R, Hohage A, Deckert J, Pfuhlmann B (2013). Interaction of valproic acid and amitriptyline - analysis of therapeutic drug monitoring data under naturalistic conditions. J Clin Psychopharmacol 33:561-564.
29. Vandel S, Bertschy G, Jounet JM, Allers G (1988). Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit 10:386-389.
30. Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J (2011). Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 52:70-71.
31. Wen X,Wang JS, KivistöKT, Neuvonen PJ, Backman JT (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 52:547-553.
32. Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR (1996). Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 60:48-53. (Pubitemid 26279220)